Undisclosed PDL1 x CD28 XmAb bsAb therapeutic
/ Xencor
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 08, 2021
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
(Businesswire)
- "Preclinical Data Presentations: New data from four preclinical-stage programs, including Xencor’s IL-12-Fc cytokine program, PD-L1 x CD28 bispecific antibody program, TGFβR2 bispecific antibody platform, and bispecific NK cell engager platform, will also be presented at the SITC Annual Meeting."
Preclinical • Oncology
1 to 1
Of
1
Go to page
1